

(19) World Intellectual Property Organization  
International Bureau

20 AUG 2004

(43) International Publication Date  
28 August 2003 (28.08.2003) ✓

PCT

(10) International Publication Number  
WO 03/070203 A1 ✓(51) International Patent Classification<sup>7</sup>: A61K 7/00, 35/74

(21) International Application Number: PCT/EP03/01685

(22) International Filing Date: 18 February 2003 (18.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02075703.5 21 February 2002 (21.02.2002) EP

(71) Applicants (for all designated States except US): SOCIETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box 353, CH-1800 Vevey (CH). L'OREAL [FR/FR]; 14, rue Royale, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRETON, Lionel [FR/FR]; 14, rue de Satory, F-78000 Versailles (FR). BUREAU-FRANZ, Isabelle [FR/CH]; 27, ch. du Mottier, CH-1052 Le Mont-Sur-Lausanne (CH). FANCHON, Chantal [FR/FR]; 105, quai Branly, F-75015 Paris (FR).

(74) Agent: THOMAS, Alain; Avenue Nestlé 55, CH-1800 Vevey (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ; DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORALLY ADMINISTRABLE COMPOSITION FOR THE PHOTOPROTECTION OF THE SKIN

(57) Abstract: An orally administrable composition for the photoprotection of the skin which comprises the combination of (i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and (ii) at least one carotenoid or derivative, included into an orally acceptable carrier.

WO 03/070203 A1

**Orally administrable composition for the photoprotection of the skin****Field of the invention**

5 The present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical compositions, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and a method to improve the photoprotection of the skin.

10

**Background of the Invention**

15 The continuous decrease of the atmosphere's ozone layer with the concurrent increase of ultraviolet radiation reaching the planet's surface has attracted a great deal of interest in its potential consequence on human health. Although exposure to ultraviolet radiation is needed for humans to produce vitamin D, growing evidence suggests that extensive exposure to sun-light, in particular to ultraviolet radiation, causes a variety of problems in the skin, including induction of certain skin cancers and induction of accelerated skin ageing.

20

In addition to these established health concerns, research has also provided evidence suggesting that exposure to ultraviolet radiation may negatively affect a variety of immune responses in living beings both locally, within the UV-irradiated skin, and also systemically, i.e. at sites distant from the irradiated skin.

25

It is thus important to alleviate the detrimental effects of ultraviolet radiation on the skin, and also prevent the development of erythema, oedema and/or flaking or scaling (hyperkeratosis) of the skin.

30

In the art, there have been several attempts, such as by using sunscreens or other particular pharmacological agents.

In J. Invest. Dermatol., 97 (1991), 624-628 it is reported that topical application of ultraviolet radiation-absorbing compounds (sunscreens) is effective in preventing ultraviolet radiation-induced erythema and edema but cannot prevent UV-light induced immuno-suppression. This finding was confirmed by several other studies,  
5 according to which sunscreens seems to prevent inflammation or irritation but do not provide complete prophylactic protection against the immuno-suppressive effects of ultraviolet radiation.

On the other hand, In FR 2698 268 (L'Oreal) an orally administrable composition  
10 comprising a combination of at least one amino-acid, salt of copper and a mix of vitamins has been shown to protect the skin against ultraviolet radiation.

However, there is still a need in the art for an orally administrable composition, which is capable to improve and/or reinforce the photoprotective function of the skin.  
15

### **Summary of the invention**

Accordingly, in a first aspect the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a  
20 photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.

The present invention further relates to the use of a photoprotecting effective amount  
25 of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.

In a last aspect, the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to the individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least 5 one carotenoid or derivative, in an orally acceptable carrier.

The combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.

10

#### **Detailed Description of the Invention**

Within the following description, "NCC" designates Nestlé Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland). The term 15 "photoprotection" is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.

According to the present invention, the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium 20 or a culture supernatant thereof, and at least one carotenoid or derivative.

Indeed, it has now surprisingly and unexpectedly been determined that admixture of these two very specific constituents elicits an enhanced effect or response in respect of the photoprotection of the skin.

25

Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastro-intestinal wall and reducing their numbers and reducing or preventing infections. 30 Until now a number of different probiotic microorganisms have been found, which

all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.

It has now been shown that probiotics do also exert an effect in an individual's body  
5 at a location distant from the region in which they colonize it. And particularly, it has been surprisingly found that a composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.

10 In a preferred embodiment, the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*,  
15 *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, or a mixture thereof.

According to a most preferred embodiment the strains *Lactobacillus johnsonii* NCC  
20 533, *Lactobacillus paracasei* NCC 2461, *Bifidobacterium adolescentis* NCC 251 and *Bifidobacterium longum* NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris  
cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170,  
25 respectively.

The strain of *Bifidobacterium lactis* (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.

The probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder. Also culture supernatants of the microorganisms may be included in the products, 5 optionally in concentrated form. It may also be included in an encapsulated form. When using a supernatant of a probiotic's culture the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s) /metabolite (s). Method and techniques for purifying compounds and detecting the activity thereof in 10 the fractions obtained are well known to the skilled person.

The probiotic lactic acid bacteria may be present in the carrier in an amount of at least  $10^5$  cfu/g of carrier and preferably from about  $10^5$  to  $10^{15}$  cfu/ g of orally acceptable carrier, and more preferably from  $10^7$  to  $10^{12}$  cfu/g of orally acceptable 15 carrier.

The carotenoid may be a carotenoid with or without provitamin A activity. It may be  $\beta$ -carotene,  $\gamma$ -carotene,  $\alpha$ -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof. The carotenoid may be from synthetic or natural origin or contained in a 20 natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art. The carotenoid may be present in the carrier in an amount of from  $10^{-12\%}$  to 20% by weight and preferably from 0,00001 mg to 50 mg/day and more preferably from 0.001mg to 30mg/day.

25

A mixture of a plurality of lactic acid bacteria or carotenoids may also be used.

The carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic 30 microorganism and the carotenoid may be included. Examples for food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based

fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding. The nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or  
5 drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.

The composition according to the invention may further comprise bioactive molecules or yeast extracts, for example. In a preferred embodiment, the yeast is any  
10 food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina . In a preferred embodiment, the yeast may be selected from the group consisting of *Debaryomyces*, *Kluyveromyces*, *Saccharomyces*, *Yarrowia*, *Zygosaccharomyces*, *Candida* and *Rhodotorula*, and more preferably *Saccharomyces caerevisae* (baker's yeast).

15 Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least  $10^5$  cfu/ g of orally acceptable carrier, preferably from about  $10^5$  to  $10^{15}$  cfu/ g of orally acceptable carrier, and more preferably from  $10^7$  to  $10^{12}$  cfu/ g of orally acceptable carrier, said amount depending  
20 on the nature and activity of the particular yeast.

The composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.

25 The composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.

Accordingly, in another aspect, the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally  
30 administering to an individual a composition comprising a photoprotecting effective

amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.

5       The amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about  $10^5$  to  $10^{15}$  organisms, which organism may be alive or dead, and from 0,00001 mg to 50 mg of carotenoids, would usually be adequate.

10      The composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun. When the exposure period is foreseeable, it is desirable to start the consumption before the exposure and preferably 1 to 2 months before, and to prolong consumption during exposure.

15      The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application. All percentages are given by weight unless otherwise indicated.

### Examples

20      In the following examples 1 to 6,  $\beta$ -carotene is provided by Roche, Lycopene is provided by Lycored, Lyophilized *S.cerevissae* is provided by BioSpringer, *Latobacillus* CNCM I-1225 dry mix, *Lactobacillus* CNCM I-2116 or *Bifidobacterium* CNCM I-2168 dry mix are prepared so that they contain  $1.10^8$  to  $1.10^9$  organisms.

25

#### Example 1

A photoprotective daily orally administrable composition is prepared as follows:

$\beta$ -carotene    4.7 mg

30      *Latobacillus* CNCM I-1225 dry mix                                  50 mg

Glucidex IT 19 (maltodextrin powder)                                  QSP 500 mg

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

### **Example 2**

5

A photoprotective daily orally administrable composition is prepared as follows:

$\beta$ -carotene	4.7 mg
Zeaxanthine	10 mg
Latobacillus CNCM I-1225 dry mix	50 mg
Glucidex IT 19 (maltodextrin powder)	QSP 500 mg

10

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

### **Example 3**

15

A photoprotective daily orally administrable composition is prepared as follows:

$\beta$ -carotene	4.7 mg
Lycopene	2.5 mg
Bifidobacterium CNCM I-2168 dry mix	30 mg
Latobacillus CNCM I-1225 dry mix	30 mg
Glucidex IT 19 (maltodextrin powder)	QSP 500 mg

20

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

25

### **Example 4**

A photoprotective daily orally administrable composition is prepared as follows:

Lycopene	2.5 mg
Lyophilized <i>S.cerevissae</i>	75 mg
Latobacillus CNCM I-2116 dry mix	50 mg
Glucidex IT 19 (maltodextrin powder)	QSP 500 mg

30

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

**Example 5**

5

A photoprotective daily orally administrable composition is prepared as follows:

$\beta$ -carotene	4.7 mg
Lycopene	2.5 mg
Lyophilized <i>S.cerevissae</i>	75 mg
Latobacillus CNCM I-1225 dry mix	50 mg
Glucidex IT 19 (maltodextrin powder)	QSP 500 mg

10

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

15

**Example 6**

A photoprotective daily orally administrable composition is prepared as follows:

$\beta$ -carotene	4.7 mg
Lyophilized <i>S.cerevissae</i>	75 mg
Latobacillus CNCM I-1225 dry mix	50 mg
Glucidex IT 19 (maltodextrin powder)	QSP 500 mg

The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.

25

**Claims**

1. An orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.  
5
2. A composition according to claim 1, in which the lactic acid bacterium is selected from the group consisting of Lactic acid bacteria, preferably Lactobacilli and/ or  
10 Bifidobacteria.
3. A composition according to claim 1 or 2, in which the lactic acid bacterium is *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*,  
15 *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium animalis*, , *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, or a mixture thereof.
4. A composition according to one of claims 1 to 3, in which the lactic acid  
20 bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168 or CNCM I-2170.
5. A composition according to one of claims 1 to 4, in which the probiotic lactic acid bacterium is included into the carrier in a live form, semi-active or in deactivated form, preferably as a lyophilized powder attention.  
25
6. A composition according to one of claims 1 to 5, wherein the carotenoid is a carotenoid with or without provitamin A activity, such as  $\beta$ -carotene,  $\gamma$ -carotene,  $\alpha$ -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
- 30 7. A composition according to one of claims 1 to 6, wherein the carrier is a food or a pharmaceutical product, or a nutritional supplement for oral administration.

8. A composition according to claim 6, wherein the food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding.  
5
9. A composition according to claim 7, wherein the nutritional supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles,  
10 gums, or drinkable solutions or emulsions.
10. A composition according to one of claim 1 to 9, which further comprises a yeast extract or a bioactive molecule.
- 15 11. Use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier, for preparing an orally administrable composition for the protection of the skin against solar radiations and attenuating or preventing all related skin disorders.  
20
12. The use according to claim 11, in which the lactic acid bacterium is *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, or a mixture thereof.  
25
13. The use according to claim 11 or 12, wherein the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536.

14. The use according to one of claims 11 to 13, wherein the probiotic lactic acid bacterium is present in the carrier in an amount of from about  $10^5$  to  $10^{12}$  cfu/g carrier.

5        15. The use according to one of claims 11 to 13, wherein the carotenoid is present in the carrier in an amount of from  $10^{-12}\%$  to 20% by weight.

10        16. A method for improving the photoprotective function of the skin, which comprises the step of orally administering to the individual a composition comprising the combination of i) at least one probiotic lactic acid bacteria or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.

15        17. A method according to claim 16, in which the composition is according to one of claims 1 to 10.

10/505305


DT09 Rec'd PCT/PTO 20 AUG 2004

<b>I. IDENTIFICATION DU MICRO-ORGANISME</b>	
Référence d'identification donnée par le DEPOSANT :	Numéro d'ordre attribué par l'AUTORITE DE DEPOT INTERNATIONALE :
<u>La 1</u>	<u>I - 1225</u>
<b>II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE</b>	
Le micro-organisme identifié sous chiffre I était accompagné :	
<input checked="" type="checkbox"/> d'une description scientifique	
<input checked="" type="checkbox"/> d'une désignation taxonomique proposée	
(Cocher ce qui convient)	
<b>III. RECEPTION ET ACCEPTATION</b>	
La présente autorité de dépôt internationale accepte le micro-organisme identifié sous chiffre I, qu'elle a reçu le <u>30.06.1992</u> (date du dépôt initial)	
<b>IV. RECEPTION D'UNE REQUETE EN CONVERSION</b>	
La présente autorité de dépôt internationale a reçu le micro-organisme identifié sous chiffre I le <u>(date du dépôt initial)</u> et a reçu une requête en conversion du dépôt initial en dépôt conforme au Traité de Budapest le <u>(date de réception de la requête en conversion)</u>	
<b>V. AUTORITE DE DEPOT INTERNATIONALE</b>	
Nom : Collection Nationale de Cultures de Microorganismes Institut Pasteur 25, Rue du Docteur Roux Adresse : <u>75724 PARIS CEDEX 15</u>	Signature(s) de la (des) personne(s) compétente(s) pour représenter l'autorité de dépôt internationale ou de l'(des) employé(s) autorisé(s)  <u>Y. CERISIER</u> Date : Paris le 02 Juillet 1992 Mme Y. CERISIER

10/505305

PCT/EP03/01685

DT09 Rec'd PCT/PTO 20 AUG 2004

<b>I. IDENTIFICATION DU MICRO-ORGANISME</b>	
Référence d'identification donnée par le DEPOSANT :  <b>NCC 2461</b>	Numéro d'ordre attribué par l'AUTORITE DE DEPOT INTERNATIONALE :  <b>I.-2116</b>
<b>II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE</b>	
Le micro-organisme identifié sous chiffre I était accompagné :  <input checked="" type="checkbox"/> d'une description scientifique  <input checked="" type="checkbox"/> d'une désignation taxonomique proposée  (Cocher ce qui convient)	
<b>III. RECEPTION ET ACCEPTATION</b>	
La présente autorité de dépôt internationale accepte le micro-organisme identifié sous chiffre I, qu'elle a reçu le <b>12 JANVIER 1999</b> (date du dépôt initial) 1	
<b>IV. RECEPTION D'UNE REQUETE EN CONVERSION</b>	
La présente autorité de dépôt internationale a reçu le micro-organisme identifié sous chiffre I le <b>12 JANVIER 1999</b> (date du dépôt initial) et a reçu une requête en conversion du dépôt initial en dépôt conforme au Traité de Budapest le <b>12 FÉVRIER 1999</b> (date de réception de la requête en conversion)	
<b>V. AUTORITE DE DEPOT INTERNATIONALE</b>	
Nom :  <b>CNCM</b> Collection Nationale de Cultures de Microorganismes	Signature(s) de la (des) personne(s) compétente(s) pour représenter l'autorité de dépôt internationale ou de l'(des) employé(s) autorisé(s) : <b>Mme Y. CERISIER</b> Directeur Administratif de la CNCM
Adresse :  <b>INSTITUT PASTEUR</b> 28, Rue du Docteur Roux F-75724 PARIS CEDEX 15	 Date : Paris, le 12 février 1999

10/505305

PCT/EP03/01685

DT09 Rec'd PCT/PTO 20 AUG 2004

<b>I. IDENTIFICATION DU MICRO-ORGANISME</b>	
Référence d'identification donnée par le DEPOSANT :  <b>NCC 251</b>	Numéro d'ordre attribué par l'AUTORITE DE DEPOT INTERNATIONALE :  <b>I - 2168</b>
<b>II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE</b>	
Le micro-organisme identifié sous chiffre I était accompagné :  <input checked="" type="checkbox"/> d'une description scientifique <input checked="" type="checkbox"/> d'une désignation taxonomique proposée  (Cocher ce qui convient)	
<b>III. RECEPTION ET ACCEPTATION</b>	
La présente autorité de dépôt internationale accepte le micro-organisme identifié sous chiffre I, qu'elle a reçu le <b>15 MARS 1999</b> (date du dépôt initial) <sup>1</sup>	
<b>IV. RECEPTION D'UNE REQUETE EN CONVERSION</b>	
La présente autorité de dépôt internationale a reçu le micro-organisme identifié sous chiffre I le <sup>(date du dépôt initial)</sup> et a reçu une requête en conversion du dépôt initial en dépôt conforme au Traité de Budapest le <sup>(date de réception de la requête en conversion)</sup>	
<b>V. AUTORITE DE DEPOT INTERNATIONALE</b>	
Nom :  <b>CNCM</b> Collection Nationale de Cultures de Microorganismes	Signature(s) de la (des) personne(s) compétente(s) pour représenter l'autorité de dépôt internationale ou de l'(des) employé(e)s autorisé(s) : <b>Simona OZDEN</b> Directrice de la CNCM   Date : Paris, le 10 août 1999
Adresse :  <b>INSTITUT PASTEUR</b> 28, Rue du Docteur Roux F-75724 PARIS CEDEX 15	

<b>I. IDENTIFICATION DU MICRO-ORGANISME</b>	
Référence d'identification donnée par le DEPOSANT :	Numéro d'ordre attribué par l'AUTORITE DE DEPOT INTERNATIONALE :
<b>NCC 490</b>	<b>I - 2170</b>
<b>II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE</b>	
Le micro-organisme identifié sous chiffre I était accompagné :	
<input checked="" type="checkbox"/> d'une description scientifique. <input checked="" type="checkbox"/> d'une désignation taxonomique proposée <small>(Cocher ce qui convient)</small>	
<b>III. RECEPTION ET ACCEPTATION</b>	
La présente autorité de dépôt internationale accepte le micro-organisme identifié sous chiffre I, qu'elle a reçu le <b>15 MARS 1999</b> (date du dépôt initial) <sup>1</sup>	
<b>IV. RECEPTION D'UNE REQUETE EN CONVERSION</b>	
La présente autorité de dépôt internationale a reçu le micro-organisme identifié sous chiffre I le _____ (date du dépôt initial) et a reçu une requête en conversion du dépôt initial en dépôt conforme au Traité de Budapest le _____ (date de réception de la requête en conversion)	
<b>V. AUTORITE DE DEPOT INTERNATIONALE</b>	
Nom : <b>CNCM</b> Collection Nationale de Cultures de Microorganismes	Signature(s) de la (des) personne(s) compétente(s) pour représenter l'autorité de dépôt internationale ou de l'(des) employé(s) autorisé(s) : <b>Simona OZDEN</b> Directeur de la CNCM  Date : Paris, le 10 août 1999
Adresse : <b>INSTITUT PASTEUR</b> 28, Rue du Docteur Roux F-75724 PARIS CEDEX 15	

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 03/01685A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K7/00 A61K35/74

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 49877 A (GANEDEN BIOTECH INC ;FARMER SEAN (US); LEFKOWITZ ANDREW R (US)) 7 October 1999 (1999-10-07) claims 2,5,7,35 page 24, line 18 page 11, line 11 - line 13 page 23, line 1 - line 3 ---	1-10,12, 13
X	EP 1 151 673 A (NESTLE SA) 7 November 2001 (2001-11-07) claims 15,16 column 11, line 8 ---	1-10,12, 13
X	US 2001/006671 A1 (BIZUB DENNIS ET AL) 5 July 2001 (2001-07-05) claim 10 page 5, Paragraph '0064! ---	1-10,12, 13

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

1 July 2003

Date of mailing of the international search report

11/07/2003

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

## Authorized officer

Beranová, P

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 03/01685

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 609 056 A (KYOWA HAKKO KOGYO KK) 3 August 1994 (1994-08-03) claim 3 page 3, line 6 - line 9 page 3, line 24 - line 30 ---	1-10,12, 13
X	US 6 030 650 A (KAMAREI A REZA) 29 February 2000 (2000-02-29) claims 10,19 column 6, line 4 - line 8 ---	1-9,12, 13
X	EP 1 020 123 A (SITIA YOMO SPA) 19 July 2000 (2000-07-19) claim 4 column 10, line 25 ---	1-9,12, 13
X	WO 00 70972 A (LINDBERG ANNE MARIE ;WIKLANDER JOERGEN (SE); BERGGREN ANNA (SE); L) 30 November 2000 (2000-11-30) claims 3-5 page 4, paragraph 4 -----	1-9,12, 13

**INTERNATIONAL SEARCH REPORT**national application No.  
PCT/EP 03/01685**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 16 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest** The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/03/01685

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9949877	A	07-10-1999		AU 3380899 A CA 2326874 A1 EP 1067945 A2 JP 2002509891 T WO 9949877 A2	18-10-1999 07-10-1999 17-01-2001 02-04-2002 07-10-1999
EP 1151673	A	07-11-2001		EP 1151672 A1 EP 1151673 A2 AU 5223801 A BR 0110552 A CZ 20023834 A3 WO 0182715 A2 EP 1280414 A2 US 2003059501 A1 AU 9518701 A BR 0110556 A WO 0182716 A1 EP 1299006 A1	07-11-2001 07-11-2001 12-11-2001 01-04-2003 12-02-2003 08-11-2001 05-02-2003 27-03-2003 12-11-2001 01-04-2003 08-11-2001 09-04-2003
US 2001006671	A1	05-07-2001		NONE	
EP 0609056	A	03-08-1994		JP 3347381 B2 JP 6217710 A CA 2114338 A1 DE 69422066 D1 DE 69422066 T2 EP 0609056 A2 US 5756088 A	20-11-2002 09-08-1994 28-07-1994 20-01-2000 24-08-2000 03-08-1994 26-05-1998
US 6030650	A	29-02-2000		US 5985339 A AU 5397699 A WO 0065935 A1 US 6093425 A US 6039985 A US 6194009 B1	16-11-1999 17-11-2000 09-11-2000 25-07-2000 21-03-2000 27-02-2001
EP 1020123	A	19-07-2000		EP 1020123 A1 BR 9906141 A	19-07-2000 06-02-2001
WO 0070972	A	30-11-2000		AU 4969100 A CA 2374044 A1 CN 1351473 T EP 1178740 A1 JP 2003500036 T NO 20015405 A NZ 515799 A WO 0070972 A1 SE 9901856 A	12-12-2000 30-11-2000 29-05-2002 13-02-2002 07-01-2003 05-11-2001 30-05-2003 30-11-2000 24-11-2000